Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/DDDT.S97235 http://scihub22266oqcxt.onion/10.2147/DDDT.S97235 C4654530!4654530!26622168     free     free     free       Drug+Des+Devel+Ther 2015 ; 9 (ä): 6075-81 Nephropedia Template TP {{tp|p=26622168|t=2015. Apatinib for molecular targeted therapy in tumor |pdf=|usr=}}{{26622168}} gab.com Text Apatinib for molecular targeted therapy in tumor JO: Drug Des Devel Ther http://www.kidney.de/pget.php?&tw=1&pmid=26622168 #FOAvip As tumor angiogenesis is one of the hallmarks of cancer, the inhibition of vascular endothelial growth factor signaling has become an attractive anticancer approach. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2, has demonstrated encouraging anticancer activity across a broad range of malignancies, including gastric cancer, non-small-cell lung cancer, breast cancer, and hepatocellular carcinoma. In this up-to-date review, focus is not only on the structure, mechanisms, and pharmacokinetics of apatinib, but also on summarizing clinical trials and making recommendations of apatinib for patients with advanced solid tumors. Twit Text FOAVip Apatinib for molecular targeted therapy in tumor ????Drug Des Devel Ther http://www.kidney.de/pget.php?&tw=1&pmid=26622168 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26622168 #FOAvip English Wikipedia <ref>{{Cite pmid|26622168}}</ref> Apatinib for molecular targeted therapy in tumor #MMPMID26622168 Zhang H Drug Des Devel Ther 2015[]; 9 (ä): 6075-81 PMID26622168show ga As tumor angiogenesis is one of the hallmarks of cancer, the inhibition of vascular endothelial growth factor signaling has become an attractive anticancer approach. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2, has demonstrated encouraging anticancer activity across a broad range of malignancies, including gastric cancer, non-small-cell lung cancer, breast cancer, and hepatocellular carcinoma. In this up-to-date review, focus is not only on the structure, mechanisms, and pharmacokinetics of apatinib, but also on summarizing clinical trials and making recommendations of apatinib for patients with advanced solid tumors. äApatinib for molecular targeted therapy in tumor (epmc).pdf DeepDyve Pubget Overpricing